Alexander G Majouga
Overview
Explore the profile of Alexander G Majouga including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
82
Citations
579
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Machulkin A, Petrov S, Bodenko V, Larkina M, Plotnikov E, Yuldasheva F, et al.
ACS Pharmacol Transl Sci
. 2024 May;
7(5):1457-1473.
PMID: 38751647
Lu-labeled small-molecule prostate-specific membrane antigen (PSMA) targeted tracers are therapeutic agents for metastatic castration-resistant prostate cancer. Optimizing molecular design holds the potential to further enhance the pharmacokinetic properties of PSMA-targeted...
2.
Uspenskaia A, Krasnikov P, Majouga A, Beloglazkina E, Machulkin A
Biochemistry (Mosc)
. 2023 Sep;
88(7):953-967.
PMID: 37751866
Fluorescent dyes are widely used in histological studies and in intraoperative imaging, including surgical treatment of prostate cancer (PC), which is one of the most common types of cancerous tumors...
3.
Hasnowo L, Larkina M, Plotnikov E, Bodenko V, Yuldasheva F, Stasyuk E, et al.
Int J Mol Sci
. 2023 Aug;
24(15).
PMID: 37569582
Prostate-specific membrane antigen (PSMA) has been identified as a target for the development of theranostic agents. In our current work, we describe the design and synthesis of novel N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-(S)-L-lysine (DCL)...
4.
Zyk N, Garanina A, Plotnikova E, Ber A, Nimenko E, Dashkova N, et al.
Int J Mol Sci
. 2023 Jul;
24(14).
PMID: 37511087
Prostate cancer is the second most common cancer among men. We designed and synthesized new ligands targeting prostate-specific membrane antigen and suitable for bimodal conjugates with diagnostic and therapeutic agents....
5.
Nizamov T, Amirov A, Kuznetsova T, Dorofievich I, Bordyuzhin I, Zhukov D, et al.
Nanomaterials (Basel)
. 2023 Mar;
13(5).
PMID: 36903693
Nowadays, magnetoelectric nanomaterials are on their way to finding wide applications in biomedicine for various cancer and neurological disease treatment, which is mainly restricted by their relatively high toxicity and...
6.
Krasnovskaya O, Akasov R, Spector D, Pavlov K, Bubley A, Kuzmin V, et al.
ACS Appl Mater Interfaces
. 2023 Feb;
15(10):12882-12894.
PMID: 36854172
Controlled photoreduction of Pt(IV) prodrugs is a challenging task due to the possibility of targeted light-controlled activation of anticancer agents without affecting healthy tissues. Also, a conjugation of photosensitizers and...
7.
Ivanenkov Y, Kukushkin M, Beloglazkina A, Shafikov R, Barashkin A, Ayginin A, et al.
Molecules
. 2023 Feb;
28(3).
PMID: 36770991
Novel variously substituted thiohydantoin-based -indolinones were prepared using a regio- and diastereoselective synthetic route from 5-arylidene-2-thiohydantoins, isatines, and sarcosine. The obtained molecules were subsequently evaluated in vitro against the cancer...
8.
Maklakova S, Lopukhov A, Khudyakov A, Kovalev S, Mazhuga M, Chepikova O, et al.
RSC Med Chem
. 2023 Feb;
14(1):56-64.
PMID: 36760736
Statins are effective 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-R) inhibitors, which are successfully used for cardiovascular disease treatment. Statins' side effects are generally attributed to poor bioavailability and hepatoselectivity, which are...
9.
Machulkin A, Nimenko E, Zyk N, Uspenskaia A, Smirnova G, Khan I, et al.
Molecules
. 2022 Dec;
27(24).
PMID: 36557929
Prostate cancer is the second most common type of cancer among men. The main method of its treatment is androgen deprivation therapy, which has a wide range of side effects....
10.
Kholodenko I, Kholodenko R, Majouga A, Yarygin K
Curr Issues Mol Biol
. 2022 Nov;
44(11):5153-5172.
PMID: 36354663
Over the past two decades, mesenchymal stem cells (MSCs) have shown promising therapeutic effects both in preclinical studies (in animal models of a wide range of diseases) and in clinical...